Aliases & Classifications for Neuritis

MalaCards integrated aliases for Neuritis:

Name: Neuritis 12 55 44 15 73
Peripheral Neuritis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1803
MeSH 44 D009443
NCIt 50 C116381
UMLS 73 C0027813

Summaries for Neuritis

MalaCards based summary : Neuritis, also known as peripheral neuritis, is related to neuromyelitis optica and optic neuritis, and has symptoms including neuralgia and sciatica. An important gene associated with Neuritis is PMP2 (Peripheral Myelin Protein 2), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, lung and brain, and related phenotypes are hematopoietic system and behavior/neurological

Wikipedia : 76 Neuritis (/njʊəˈraɪtɪs/) is inflammation of a nerve or the general inflammation of the peripheral... more...

Related Diseases for Neuritis

Diseases related to Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 427)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 33.1 AQP4 MBP MOG
2 optic neuritis 32.2 AQP4 MAG MBP MOG MPZ MT-ND4
3 optic nerve disease 31.8 AQP4 MBP MOG MT-ND4
4 transverse myelitis 30.9 AQP4 MBP TNF
5 acute disseminated encephalomyelitis 30.8 AQP4 MBP MOG
6 myelitis 30.6 AQP4 MBP MOG TNF
7 miller fisher syndrome 30.3 MAG TNF
8 allergic encephalomyelitis 30.3 CXCL10 MBP MOG
9 chronic inflammatory demyelinating polyradiculoneuropathy 30.2 IFNG MPZ PMP22
10 aseptic meningitis 30.1 IFNG IL1B TNF
11 q fever 30.1 IFNG IL1B TNF
12 acquired immunodeficiency syndrome 29.9 IFNG IL1B TNF
13 laryngitis 29.8 IL1B TNF
14 typhoid fever 29.8 IFNG IL1B TNF
15 lymphadenitis 29.8 IFNG IL1B TNF
16 chlamydia 29.7 IFNG IL1B TNF
17 meningitis 29.7 CCL2 IFNG IL1B TNF
18 polyneuropathy 29.6 MAG MBP MPZ PMP22
19 cytomegalovirus infection 29.5 CCL5 IFNG TNF
20 rubella 29.3 IL4 MOG TNF
21 arthritis 29.2 CCL2 IFNG IL1B TNF
22 poliomyelitis 29.1 IFNG IL4 TNF
23 schistosomiasis 29.0 IFNG IL4 TNF
24 pulmonary tuberculosis 28.9 IFNG IL4 TNF
25 charcot-marie-tooth disease 28.9 MAG MBP MPZ PMP2 PMP22
26 scleritis 28.7 CCL2 IL4 TNF
27 myasthenia gravis 28.7 IFNG IL4 MBP TNF
28 pneumonia 28.7 CCL2 CCL5 IL1B TNF
29 chikungunya 28.6 CCL2 CCL5 IL1B TNF
30 toxoplasmosis 28.4 IFNG IL1B IL4 TNF
31 colitis 28.4 IFNG IL1B IL4 TNF
32 uveitis 28.2 CCL2 CXCL10 IFNG IL4 TNF
33 encephalitis 27.8 AQP4 CCL2 CCL5 CXCL10 IL1B MOG
34 polyradiculoneuropathy 27.6 CCL5 IFNG MAG MBP MPZ PMP2
35 systemic lupus erythematosus 27.1 CCL2 CCL5 CXCL10 IFNG IL4 TNF
36 relapsing-remitting multiple sclerosis 27.1 AQP4 CCL5 IFNG IL4 MBP MOG
37 rheumatoid arthritis 26.7 CCL2 CCL5 IFNG IL1B IL4 TNF
38 malaria 25.8 CCL2 CCL5 CXCL10 IFNG IL1B IL4
39 psoriasis 25.6 CCL2 CCL5 CXCL10 IFNG IL1B IL4
40 demyelinating disease 25.4 AQP4 CCL2 CCL5 CXCL10 IFNG IL1B
41 multiple sclerosis 24.5 AQP4 CCL2 CCL5 CXCL10 IFNG IL1B
42 acute retrobulbar neuritis 12.2
43 brachial plexus neuritis 12.1
44 isolated optic neuritis 12.0
45 amyotrophy, hereditary neuralgic 11.7
46 chronic relapsing inflammatory optic neuropathy 11.5
47 parsonage turner syndrome 11.5
48 flynn-aird syndrome 11.5
49 vestibular neuronitis 11.5
50 amyotrophic neuralgia 11.3

Graphical network of the top 20 diseases related to Neuritis:



Diseases related to Neuritis

Symptoms & Phenotypes for Neuritis

UMLS symptoms related to Neuritis:


neuralgia, sciatica

MGI Mouse Phenotypes related to Neuritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 IFNG MPZ IL1B IL4 MAG TNF
2 behavior/neurological MP:0005386 10.02 MOG IFNG MPZ PMP2 PMP22 MAG
3 homeostasis/metabolism MP:0005376 10 IFNG MPZ PMP2 IL1B PMP22 IL4
4 immune system MP:0005387 9.93 MPZ IL1B IL4 MAG TNF AQP4
5 nervous system MP:0003631 9.73 MPZ IL1B PMP2 PMP22 IL4 MAG
6 vision/eye MP:0005391 9.17 IFNG PMP22 IL4 TNF AQP4 MBP

Drugs & Therapeutics for Neuritis

Drugs for Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 837)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
4
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2 147245-92-9 3081884
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
7
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
8
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
9
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-12-2 119
10
Stavudine Approved, Investigational Phase 4,Phase 3 3056-17-5 18283
11
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
12
Histamine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 75614-87-8, 51-45-6 774
13
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
14
Imipramine Approved Phase 4 50-49-7 3696
15
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
16
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
17
Etoricoxib Approved, Investigational Phase 4,Phase 2 202409-33-4 123619
18
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
19
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
20
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Not Applicable 15687-27-1 3672
21
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
22
Capsaicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 404-86-4 1548943
23
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
25
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
26
Mannitol Approved, Investigational Phase 4,Phase 1,Phase 2 69-65-8 453 6251
27
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
28
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
29
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
30
Naloxone Approved, Vet_approved Phase 4,Phase 2 465-65-6 5284596
31
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 76-42-6 5284603
32
Nabilone Approved, Investigational Phase 4,Phase 3,Phase 2 51022-71-0 5284592
33
Levobupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable 27262-47-1 92253
34
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
35
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
36
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
37
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
38
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
39
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
40
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-48-6 2160
41
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
42
Minocycline Approved, Investigational Phase 4,Phase 2,Not Applicable 10118-90-8 5281021
43
Perphenazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-39-9 4748
44
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
45
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 298-46-4 2554
46
Oxcarbazepine Approved Phase 4,Phase 2,Not Applicable 28721-07-5 34312
47
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
48
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2 1972-08-3 16078
49
Ethanol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 64-17-5 702
50
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 1302 156391

Interventional clinical trials:

(show top 50) (show all 2502)
# Name Status NCT ID Phase Drugs
1 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
4 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
5 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
6 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
7 Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY Unknown status NCT00235222 Phase 4 stavudine
8 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
9 A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy Unknown status NCT01875562 Phase 4 Qishe Pill
10 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
11 Duration of Antibiotic Therapy in Community - Acquired Pneumonia Unknown status NCT01492387 Phase 4
12 Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain Unknown status NCT02846701 Phase 4 duloxetine
13 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
14 Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy Unknown status NCT01204008 Phase 4
15 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
16 Preventing Pain After Heart Surgery Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
17 Comparison of Intravenous Ibuprofen and Paracetamol in Patients With Sciatica Presented to the Emergency Department Unknown status NCT02777320 Phase 4 paracetamol;Ibuprofen
18 IV Paracetamol vs IV Morphine vs Placebo in Sciatalgia Unknown status NCT02504996 Phase 4 Paracetamol;morphine;Placebo
19 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
20 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
21 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
22 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
23 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
24 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
25 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
26 Dexamethasone & Bupivacaine vs Bupivacaine Alone in Combined Femoral and Sciatic Nerve Block for Perioperative Analgesia in Patients Undergoing Lower Limb Surgeries Completed NCT02576782 Phase 4 Perineural Dexamethasone and bupivacaine;Systemic Dexamethasone plus perineural bupivacaine;intravenous saline plus perineural bupivacaine
27 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
28 Uniform Multidrug Therapy Regimen for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
29 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
30 Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
31 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
32 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
33 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
34 Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109) Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
35 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
36 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
37 Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
38 Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
39 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
40 Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
41 A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN) Completed NCT00156078 Phase 4 pregabalin
42 A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
43 Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
44 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP Completed NCT00407511 Phase 4 Pregabalin
45 Intrathecal Bolus Doses of Ziconotide Completed NCT01373983 Phase 4 Ziconotide
46 Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery Completed NCT02691442 Phase 4 Ropivacaine 0.75%;Levobupivacaine 0.5%;Levobupivacaine 0.5% + epinephrin 1/200000
47 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
48 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
49 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
50 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch

Search NIH Clinical Center for Neuritis

Cochrane evidence based reviews: neuritis

Genetic Tests for Neuritis

Anatomical Context for Neuritis

MalaCards organs/tissues related to Neuritis:

41
Spinal Cord, Lung, Brain, Testes, Bone, Cortex, Skin

Publications for Neuritis

Articles related to Neuritis:

(show top 50) (show all 1172)
# Title Authors Year
1
Valuable Insights Into Visual Neuroplasticity After Optic Neuritis. ( 29297048 )
2018
2
Early Nodal and Paranodal Disruption in Autoimmune Optic Neuritis. ( 29444299 )
2018
3
Clinical value of 4-hour delayed gadolinium-Enhanced 3D FLAIR MR Images in Acute Vestibular Neuritis. ( 29330961 )
2018
4
Vestibular paroxysmia in vestibular neuritis: A case report. ( 29910862 )
2018
5
Why Therapeutic Compliance in Optic Neuritis Deserves to Be More Than Just a Footnote: Response. ( 29923869 )
2018
6
Binocular cyclotorsion in superior vestibular neuritis. ( 29967552 )
2018
7
Roles of macrophage migration inhibitory factor in Guillain-BarrAc syndrome and experimental autoimmune neuritis: beneficial or harmful? ( 29856236 )
2018
8
Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. ( 29297053 )
2018
9
Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis. ( 29957387 )
2018
10
The extent of vestibular impairment is important in recovery of canal paresis of patients with vestibular neuritis. ( 29866420 )
2018
11
Paediatric ADEM followed by optic neuritis: disease course, treatment response and outcome. ( 29443442 )
2018
12
Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. ( 29259999 )
2018
13
Association of Optic Neuritis with <i>CYP4F2</i> Gene Single Nucleotide Polymorphism and IL-17A Concentration. ( 29736281 )
2018
14
Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis. ( 29913164 )
2018
15
Guillain-BarrAc syndrome and optic neuritis after Mycoplasma pneumoniae infection. ( 29429558 )
2018
16
Hypertrophic neuritis causing tetraparesis in a cat. ( 29925717 )
2018
17
Active Leprosy Neuritis Detected on FDG PET/CT. ( 29261639 )
2018
18
Vestibular neuritis selectively involving posterior canal and utricle. ( 29938335 )
2018
19
Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. ( 29363529 )
2018
20
Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. ( 29802557 )
2018
21
MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. ( 29808469 )
2018
22
Brachial plexitis or neuritis? MRI features of lesion distribution in Parsonage-Turner syndrome. ( 29461642 )
2018
23
Beneficial or Harmful Role of Macrophages in Guillain-BarrAc Syndrome and Experimental Autoimmune Neuritis. ( 29853789 )
2018
24
Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein. ( 29972029 )
2018
25
High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. ( 29249380 )
2018
26
Early Diagnosis of Recurrent Optic Neuritis Using Contrast-Enhanced T2 Fluid-attenuated Inversion Recovery Imaging: a Case Report. ( 29976284 )
2018
27
The unfaithful neuritis. ( 29859200 )
2018
28
Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis. ( 29766684 )
2018
29
Why Therapeutic Compliance in Optic Neuritis Deserves to be More Than Just a Footnote. ( 29901490 )
2018
30
Recurrent idiopathic neuroretinitis as a spectrum of atypical optic neuritis: a case report and literature review. ( 29538599 )
2018
31
Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. ( 29540658 )
2018
32
Typical optic neuritis? ( 29941727 )
2018
33
Relapsing acute disseminated encephalomyelitis followed by optic neuritis in children; a clinical entity associated with anti-MOG antibody. ( 29790244 )
2018
34
Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis Using Conventional Magnetic Resonance Imaging Combined With Readout-Segmented Echo-Planar Diffusion-Weighted Imaging. ( 29787495 )
2018
35
Erratum: Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. ( 29417957 )
2018
36
MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. ( 29670575 )
2018
37
Retinal nerve fiber layer and ganglion cell layer changes on optical coherence tomography in early multiple sclerosis and optic neuritis cases. ( 29283135 )
2018
38
Advanced diffusion-weighted imaging in patients with optic neuritis deficit - value of reduced field of view DWI and readout-segmented DWI. ( 29417865 )
2018
39
Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases. ( 29856159 )
2018
40
Rituximab was effective for acute disseminated encephalomyelitis followed by recurrent optic neuritis with anti-myelin oligodendrocyte glycoprotein antibodies. ( 29661590 )
2018
41
Baseline Brain Activity Changes in Patients With Single and Relapsing Optic Neuritis. ( 29731712 )
2018
42
Time to steroid treatment in severe acute optic neuritis. ( 29931830 )
2018
43
Macular choroidal thickness and peripapillary retinal nerve fiber layer thickness in normal adults and patients with optic atrophy due to acute idiopathic demyelinating optic neuritis. ( 29856811 )
2018
44
Incidence and Causes of Overdiagnosis of Optic Neuritis. ( 29222573 )
2018
45
Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. ( 29445944 )
2018
46
Clinical Characteristics of Pediatric Optic Neuritis With Myelin Oligodendrocyte Glycoprotein Seropositive: A Cohort Study. ( 29778487 )
2018
47
A Pediatric Case of Relapsing-Remitting Multiple Sclerosis Onset following Varicella Zoster Ophthalmicus with Optic Neuritis. ( 29785316 )
2018
48
Unusual case of cerebral demyelination and bilateral optic neuritis in an infant with suppurative BCG lymphadenitis. ( 29848532 )
2018
49
MRI Findings in Varicella Zoster Trigeminal Neuritis Without Rash. ( 29399793 )
2018
50
Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. ( 29938337 )
2018

Variations for Neuritis

Expression for Neuritis

Search GEO for disease gene expression data for Neuritis.

Pathways for Neuritis

Pathways related to Neuritis according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 CCL2 CCL5 CXCL10 IFNG IL1B IL4
2
Show member pathways
13.22 CCL2 CCL5 CXCL10 IL1B IL4 TNF
3
Show member pathways
12.93 CCL2 CCL5 CXCL10 IFNG IL1B TNF
4
Show member pathways
12.73 CCL2 CCL5 CXCL10 IFNG IL1B IL4
5
Show member pathways
12.7 CCL5 CXCL10 IFNG IL1B TNF
6
Show member pathways
12.57 IFNG IL1B IL4 TNF
7
Show member pathways
12.52